Alpha-fetoprotein expression is a potential prognostic marker in hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 11, Issue 32, 2005, Pages 5015-5018

  Görög, Dénes ^a   Regöly Mérei, János ^a   Paku, Sándor ^a   Kopper, László ^a   Nagy, Péter ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Alpha fetoprotein; CD44; Hepatocellular carcinoma; p53; catenin

Indexed keywords

ALPHA FETOPROTEIN; BETA CATENIN; HEPATOCYTE NUCLEAR FACTOR 4; HERMES ANTIGEN; PARAFFIN; PROTEIN MLH1; PROTEIN MSH2; PROTEIN P53; TUMOR MARKER;

ARTICLE; CANCER GRADING; CELL NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DATA ANALYSIS; FREQUENCY ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LIVER CELL CARCINOMA; LIVER TUMOR; ONCOLOGICAL PARAMETERS; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SAMPLING; STATISTICAL SIGNIFICANCE;

EID: 24144482729     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i32.5015     Document Type: Article

References (24)

1. Taketa K. Alpha-fetoprotein: re-evaluation in hepatology. Hepatology 1990; 12: 1420-1432
2. Kawai HF, Kaneko S, Honda M, Shirota Y, Kobayashi K. α-fetoprotein-producing hepatoma cell lines share common expression profiles of genes in various categories demonstrated by cDNA microarray analysis. Hepatology 2001; 33: 676-691
3. Lee JS, Thorgeirsson SS. Functional and genomic implications of global gene expression profiles in cell lines from human hepatocellular cancer. Hepatology 2002; 35: 1134-1143
4. Edmondson HA, Steiner PE. Primary carcinoma of the liver. Cancer 1954; 7: 462-503
5. Brumm MC, Schulze C, Charels K, Morohoshi T, Klöppel G. The significance of alpha fetoprotein and other tumor markers in differential immunohistochemistry of primary liver tumors. Histopathology 1989; 14: 503-513
6. Peng SY, Lai PL, Chu JS. Expression and hypomethylation of alpha-fetoprotein gene in unicentric and multicentric human hepatocellular carcinomas. Hepatology 1993; 17: 35-41
7. Fujioka M, Nakashima Y, Nakashima O, Kojiro M. Immunohistologic study on the expressions of α-fetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma. Hepatology 2001; 34: 1128-1134
8. Tangkijvanich P, Anulkulkarnkusol N, Suwangool P, Lertmaharit S, Hanvivatvong O, Kullavaijaya P, Poovorawan Y. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on alpha-fetoprotein levels. J Clin Gastroenterol 2000; 31: 301-308
9. Chedid A, Ryan LM, Dayal Y, Wolf BC, Falkson G. Morphology and other prognostic factors of hepatocellular carcinoma. Arch Pathol Lab Med 1999; 123: 524-528
10. Sugo H, Takamori S, Kojima K, Beppu T, Futagawa S. The significance of p53 mutations as an indicator of the biological behavior of recurrent hepatocellular carcinomas. Surg Today 1999; 29: 849-855
11. Heinze T, Jonas S, Karsten A, Neuhaus P. Determination of the oncogenes p53 and c-ebr-B2 in the tumour cytosols of advanced hepatocellular carcinoma (HCC) and correlation to survival time. Anticancer Res 1999; 19: 2501-2503
12. Endo K, Terada T. Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression and patient survival. J Hepatol 2000; 32: 78-84
13. Washington K, Telen MJ, Gottfried MR. Expression of cell adhesion molecule CD44 in primary tumors of the liver: an immunohistochemical study. Liver 1997; 17: 17-23
14. Funayama N, Fagotto F, McCrea P, Gumbiner BM. Embryonic axis induction by the armadillo repeat domain of β-catenin: evidence for intracellular signaling. J Cell Biol 1995; 128: 959-968
15. Terris B, Pineau P, Bregeaud L, Valla D, Belghiti J, Tiollais P, Degott C, Dejean A. Close correlation between beta-catenin gene alterations and nuclear accumulation of the protein in human hepatocellular carcinomas. Oncogene 1999; 18: 6583-6588
16. De La Coste A, Romagnolo B, Billuart P, Renard CA, Buendia MA, Soubrane O, Fabre M, Chelly J, Beldjord C, Kahn A, Perret C. Somatic mutations of the b-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 1998; 95: 8847-8851
17. Suzuki T, Yano H, Nakashima Y, Kojiro M. Beta-catenin expression in hepatocellular carcinoma: a possible participation of beta-catenin in the dedifferentiation process. J Gastroenterol Hepatol 2002; 17: 994-1000
18. Van Nhieu JT, Renard CA, Wei Y, Cherqui D, Zafrani ES, Buendia MA. Nuclear accumulation of mutated β-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am J Pathol 1999; 155: 703-710
19. Vona G, Estepa L, Beroud C, Damotte D, Capron F, Nalpas B, Mineur A, Franco D, Lacour B, Pol S, Brechot C, Paterlini-Brechot P. Impact of cytomorphological detection of circulating tumor cells in patients with liver cancer. Hepatology 2004; 39: 792-798
20. Hsu HC, Jeng YM, Mao TL, Chu JS, Lai PL, Peng SY. β-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favourable prognosis. Am J Pathol 2000; 157: 763-770
21. Mao TL, Chu J, Jeng Y, Lai P, Hsu H. Expression of mutant nuclear β-catenin correlates with non-invasive hepatocellular carcinoma, absence of portal vein spread and good prognosis. J Pathol 2001; 193: 95-101
22. Laurent-Puig P, Legoix P, Bluteau O, Belghiti J, Franco D, Binot F, Monges G, Thomas G, Bioulac-sage P, Zucman-Rossi J. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocacinogenesis. Gastroenterology 2001; 120: 1763-1773
23. Calvisi DF, Factor VM, Loi R, Thorgeirsson SS. Activation of β-catenin hepatocarcinogenesis in transgenic mouse models: relationship to phenotype and tumor grade. Cancer Res 2001; 61: 2085-2091
24. Calvisi DF, Factor VM, Ladu S, Thorgeirsson SS. Disruption of β-catenin pathway or genomic instability define two distint categories of liver cancer in transgenic mice. Gastroenterology 2004; 126: 1374-1386